Today PHARMAC announced the approval of a proposal to fund pemetrexed for the treatment of mesothelioma and non-small cell lung cancer (NSCLC).
Says Philip Hope of Lung Foundation New Zealand;
“We were pleased to be informed today that pemetrexed will be funded in the public health system from the 1st November 2017.”
“Pemetrexed has improved tolerability compared to current treatments and it is an important treatment option for patients with mesothelioma and non-small cell lung cancer (NSCLC).”
“New Zealand has waited for more than a decade to have funded access to pemetrexed and this is one of the treatments we have been advocating for on behalf of patients and their families.”